Navigation Links
Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
Date:6/2/2009

IBD

IBD represents a group of chronic, progressive, recurring and debilitating inflammatory disorders of the gastrointestinal tract. Although IBD has no known cause, there is a presumed genetic component to susceptibility. It is estimated that Crohn's disease and ulcerative colitis, the two main types of IBD, together affect more than one million individuals in the U.S. The main difference between Crohn's disease and ulcerative colitis is the location and nature of the inflammation. Because the symptoms of Crohn's disease and ulcerative colitis are so similar, it is sometimes difficult to establish a definite diagnosis. However, differentiating between the two diseases is extremely important as treatment is often very different.

About Prometheus

Prometheus Laboratories Inc. is a specialty pharmaceutical and diagnostic company committed to developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and intends to apply these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary, high-value diagnostic testing services. By integrating pharmaceutical products and diagnostic testing services, Prometheus believes it can address the full continuum of care, thereby providing physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego.


'/>"/>
SOURCE Prometheus Laboratories Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
2. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
3. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
4. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
5. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
7. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
8. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
9. Spirus Medical Announces Complete Examinations of the Small Intestine by Physicians Using Endo-Ease(TM)
10. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
11. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Concord Medical Services Holdings ... CCM ), a leading specialty hospital management solution provider ... diagnostic imaging centers in China , ... of Directors declared a special cash dividend of US$0.30 ... ("ADS")) on the Company,s outstanding ordinary shares. The total ...
(Date:7/28/2014)... July 28, 2014 ... 2,5 Millionen £ investiert hat, um die ... Gesundheits-, Pharma- und Logistikbranche zu erfüllen. Albion ...      (Photo: http://photos.prnewswire.com/prnh/20140728/697982 ) ... OmPrompt sein beschleunigtes Wachstum mit Investitionen in ...
(Date:7/28/2014)... NEW PROVIDENCE, N.J. , July 28, 2014 /PRNewswire/ ... meet with Linde,s Healthcare division experts at the ... at McCormick Place in Chicago, Illinois ... nothing less than complete confidence in a reliable medical ... Segment manager. "Linde understands the importance of this critical ...
Breaking Medicine Technology:Concord Medical Declares Special Dividend 2OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2
... Ill. and LONDON, Sept. 23 Following today’s announcements ... the European Medicines Agency (EMA) for rosiglitazone in the ... Takeda Pharmaceuticals Europe Limited (“Takeda”) underscore the company’s commitment ... and to the millions of people living with type ...
... Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two ... of 1,800 Real-World Patients Compared XIENCE V to the Newer-Generation TAXUS® Liberte®,-- ... Performance in Key Safety and Efficacy... -- ABBOTT PARK, Ill., Sept. 23 ... ...
Cached Medicine Technology:Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S. 2Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S. 3Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S. 4Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 2Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 3Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 4Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 5Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 6Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 7Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 8Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 9
(Date:7/28/2014)... 28, 2014 Thousands of DePuy Pinnacle ... of individuals who were allegedly injured by a metal-on-metal ... move forward in U.S. District Court, Northern District of ... issued on July 18, 2014, U.S. District Judge Ed ... the Plaintiffs’ Steering Committee that sought the deposition of ...
(Date:7/28/2014)... Braintree, Massachusetts (PRWEB) July 28, 2014 ... the Summit Provider Exchange technology solution ... office integration efforts and support collaboration with their ... 242 bed acute-care medical center located in New ... 800,000 seasonal visitors with a variety of inpatient ...
(Date:7/28/2014)... July 28, 2014 (HealthDay News) --,The more chronic medical ... life expectancy may be, a new study claims. ... multiple health issues, scientists at Johns Hopkins Bloomberg School ... help explain why gains in life expectancy are slowing ... diseases such as diabetes, kidney disease and heart failure ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July 28, 2014 ... irregularities are more likely to get a pacemaker than people ... study of more than 16,000 people found that those with ... a pacemaker than those without the memory-robbing condition. ... dementia are so much more likely to be treated with ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Parker Waichman LLP, ... fighting to ensure that the heroes of 9/11 are never ... has announced an important deadline. According to a VCF ... with a covered cancer on or before October 12, 2012 ... 2014. First responders and others who were allegedly injured by ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 3
... and Fertilisers and Steel Ramvilas Paswan announced that central ... India//, in order to promote and encourage studies and ... Friday that his ministry would set up four new ... Pharmaceutical Education and Research (NIPER) in Hajipur in Bihar, ...
... Johnstone, 28, was suffering from Deep Vein Thrombosis since four ... after doctors told her that she no longer suffered Deep ... blood clot that had formed in her legs moved up ... lungs. ,Kathy and Norman, Karen’s parents, absolutely devastated are ...
... Omega-3 fish oil capsules could boost the brainpower of youngsters ... Newhall Park Primary School in Bradford, Britain, gave a daily ... between eight and nine for about nine months and found ... of Daily Mail. ,According to the study, 74 ...
... plans to spend in this financial year $21 billion ... doubts on whether this enormous expenditure is paying off, ... the expenditure is paying off and is more successful ... is now available on line is due to be ...
... A Government official reports, ‘Indonesia hasn’t shared the genetic information ... of disease control and environment, Nyoman Kandun//, at the Indonesian ... considered and discussed by the Government before any public release ... has been used for research purpose. ,A chain ...
... have fallen by 6,000 in the last year.,Previous results show ... last year//. But this year it reveals a steep fall ... months – says Health Minister Paul Goggins. ,He ... and he assures that necessary steps will be taken to ...
Cached Medicine News:Health News:New Study Conducted To Evaluate The Success Of The Federal governments Funds For HIV/AIDS 2
Binocular indirect ophthalmic lenses. General diagnosis & treatment....
Binocular indirect ophthalmic lenses. Ultra-High resolutions viewing of posterior pole....
... super series slit ... Variable retinal scanning ... fundus diagnostic capability, ... potential field of ...
Volk indirect lenses. Wide field retinal diagnosis & treatment....
Medicine Products: